LifePlan Financial LLC Acquires Shares of 2,714 Danaher Corporation $DHR

Key Points

• LifePlan Financial LLC acquired 2,714 shares of Danaher Corporation, valued at approximately $536,000, in the second quarter, as reported in its 13F filing with the SEC.
• Danaher has received a mix of ratings from analysts, with a current consensus rating of "Moderate Buy" and an average price target of $246.35 per share.
• The company announced a quarterly dividend of $0.32 per share, representing a dividend yield of 0.7%, to be paid on October 31st to stockholders of record as of September 26th.

LifePlan Financial LLC purchased a new position in Danaher Corporation (NYSE:DHR - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,714 shares of the conglomerate's stock, valued at approximately $536,000.

Several other hedge funds have also recently modified their holdings of the business. Hills Bank & Trust Co raised its stake in shares of Danaher by 0.3% in the first quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock worth $3,693,000 after purchasing an additional 53 shares during the last quarter. Sageworth Trust Co grew its holdings in Danaher by 2.3% during the first quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after purchasing an additional 54 shares during the period. 1834 Investment Advisors Co. grew its holdings in Danaher by 3.3% during the first quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after purchasing an additional 54 shares during the period. Rakuten Securities Inc. grew its holdings in Danaher by 33.3% during the first quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after purchasing an additional 56 shares during the period. Finally, Kingswood Wealth Advisors LLC grew its holdings in Danaher by 1.6% during the first quarter. Kingswood Wealth Advisors LLC now owns 3,466 shares of the conglomerate's stock valued at $710,000 after purchasing an additional 56 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wells Fargo & Company dropped their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research note on Tuesday, September 2nd. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Barclays reaffirmed an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Finally, Guggenheim restated a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $246.35.

Danaher Price Performance

Shares of Danaher stock opened at $188.24 on Tuesday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The business has a 50-day moving average price of $200.98 and a 200 day moving average price of $198.64. The firm has a market cap of $134.79 billion, a PE ratio of 40.05, a P/E/G ratio of 2.65 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period in the previous year, the business earned $1.72 EPS. Danaher's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is currently 27.23%.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 11.20% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.